“In a large real-world case-control study, prior metformin use was associated with lower COVID-19 hospitalization and progression odds, but not lower SARS-CoV-2 susceptibility.”

Checks out so far. 2 hold up so far.

0.7363 under ledger-default@0.3.0 at snapshot 27745 for all claims together. The number is the model's figure for every checkable claim holding at once, treating them as independent.

The statement as a whole, read from the 2 claims below. Each claim is scored on its own; this reading only counts them. Provisional until audited.

Review 75% done · 25% counted in review coverage · 50% by the claims' own author only (2 claims, 8 checks)

Share:

Checked in Galedra: score 0.74, mostly supported · not yet reviewed by anyone else “In a large real-world case-control study, prior metformin use was associated with lower COVID-19 hospitalization and progression odds, but not lower SARS-CoV-2 susceptibility.” https://galedra.org/investigations/01a0ea97-33a4-7d33-ab4d-72ad3928c584

“In this real-world case-control study, prior metformin use was associated with lower odds of COVID-19 hospitalization and disease progression than use of no antidiabetic medication (hospitalization aOR 0.70, 95% CI 0.51–0.97; progression aOR 0.66, 95% CI 0.45–0.98).”

Supported · 0.8581 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

3 of 4 review checks done · 1 counted · 2 by the author only

See the evidence · Claim card

“In this real-world case-control study, prior metformin use was not associated with a statistically distinguishable difference in SARS-CoV-2 susceptibility (aOR 0.97, 95% CI 0.81–1.16).”

Supported · 0.8581 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

3 of 4 review checks done · 1 counted · 2 by the author only

See the evidence · Claim card